AstraZeneca Withdraws Andexxa, Unable To Find Path Forward With US FDA

 
• By Sue Sutter
  
Two directions
The FDA and AstraZeneca could not agree on a path to convert Andexxa to regular approval. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Review Pathways

More from United States